FDA approves breakthrough pancreatic cancer drug proven to extend survival

The Food and Drug Administration on Wednesday rubber-stamped a new drug to treat pancreatic cancer and substantially extend the lives of patients. The drug, daraxonrasib, is produced by Revolution Medicines and was approved for individuals with metastatic pancreatic cancer who did not see success with chemotherapy. Doctors have sung the praises of the drug, and…